Search research articles
Contact Us
Filters
Showing results (131-140 of 159) with videos related to
Page
of 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B Atkins, F Stephen Hodi, John A Thompson, et al.
Leukemia Research
|
December 21, 2018
Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional study
L F Mantovani, F P S Santos, G F Perini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
N Agarwal, J Brugarolas, P Ghatalia, et al.
Ophthalmology
|
June 7, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Ophthalmology
|
February 22, 2025
Corrigendum
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
The Lancet. Oncology
|
April 30, 2022
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Robert Motzer, Camillo Porta, Boris Alekseev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
The New England Journal of Medicine
|
November 24, 2021
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome
Junne Kamihara, Kayla V Hamilton, Jessica A Pollard, et al.
The Oncologist
|
August 17, 2023
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 159) with videos related to
Sort By:
Page
of 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B Atkins, F Stephen Hodi, John A Thompson, et al.
Leukemia Research
|
December 21, 2018
Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional study
L F Mantovani, F P S Santos, G F Perini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
N Agarwal, J Brugarolas, P Ghatalia, et al.
Ophthalmology
|
June 7, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Ophthalmology
|
February 22, 2025
Corrigendum
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
The Lancet. Oncology
|
April 30, 2022
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Robert Motzer, Camillo Porta, Boris Alekseev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
The New England Journal of Medicine
|
November 24, 2021
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome
Junne Kamihara, Kayla V Hamilton, Jessica A Pollard, et al.
The Oncologist
|
August 17, 2023
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Page
of 16